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While the modern cliche “no pain, no gain”, is a commonly
used exercise motto, earlier forms of this adage were related to
work ethic. Over time, the meaning of this phrase has adapted 
so too has our understanding of biology and medicine. In this issue
of EBioMedicine, Appelt and colleagues [1] demonstrated that a
neuropeptide, calcitonin gene-related peptide (CGRP), which is
known to be involved in the pathogenesis of migraines (pain), is
essential in fracture repair (gain). This begs the question whether
the converse is also true. Whether recently FDA approved anti-
migraine therapies (no pain), which block either CGRP or the
CGRP receptor, may impair fracture healing (no gain). This impor-
tant clinical question warrants examination, especially considering
that women disproportionately suffer from both migraine and
osteoporosis-related fractures.
Migraine is a neurological disease defined by recurrent unpro-
voked headaches lasting over four hours with one or more disabling
symptoms including nausea, vomiting, dizziness, and extreme sensi-
tivity to sound and light. More than 1 billion people suffer from
migraines worldwide [2]. Migraine disproportionately affects women
with 85% of chronic migraine sufferers being women. Approximately
1 in 4 women will experience migraine in their lives. Fluctuations in
estrogen levels are associated with severe and frequent attacks,
which may explain why migraine is most common between the ages
of 1844, and in women (perimenopause typically begins when
women are in their 40’s) [2].
CGRP levels significantly rise during migraine attacks, and
injection of CGRP induces migraine-related symptoms [3]. Further
CGRP, especially the a-isoform, is primarily thought to be
involved in pain processes. Previous studies have suggested that
CGRP-expressing dorsal root ganglia respond to noxious heat andE-mail address:mkacena@iupui.edu (M.A. Kacena).
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tion of aCGRP demonstrated that aCGRP-expressing sensory neu-
rons contribute to noxious heat perception and inflammation-
induced thermal hyperalgesia but not to noxious mechanical
stimuli or mechanical hyperalgesia [4]. Therefore, based on the
large therapeutic need as well as the role of CGRP in pain and
migraine, several companies pursued the development of inhibi-
tors of CGRP or its receptor for the treatment of migraine. There
are currently 6 FDA approved therapies including: Aimovig (ere-
numab-aooe), Ajovy (fremanezumab-vfrm), Emgality (galcanezu-
mab-gnlm), Vyepti (eptinezumab-jjmr), Ubrelvy (ubrogepant),
and Nurtec ODT (rimegepant sulfate) for acute and preventative
treatment of migraine. Clinical trial results demonstrate migraine
treatment efficacy with limited to no issues regarding tolerability
and safety [5].
While there is a critical need for effective migraine treatments, as
with all therapies, benefits and risks must be balanced. Although we
are unaware of clinical studies examining the impact of use of these
drugs on development of osteoporosis or complications following
fracture, it is certainly reasonable to imagine these drugs, while help-
ing with migraine, could have a significant side effect in terms of
bone loss and impaired fracture healing.
As we recently reviewed [6], CGRP inhibits osteoclastogenesis and
bone resorption, and aCGRP increases osteoblast proliferation and
bone formation. Further, aCGRP global knockout mice (aCGRP/
mice) were found to have reduced bone formation and low bone
mass [7]. Thus, CGRP plays a critical role in regulating bone mass by
both increasing bone formation and reducing bone resorption, lead-
ing to a net gain in bone mass. Unfortunately, the reduction of aCGRP
results in low bone mass.
Herein lies a possible bone mass problem with use of migraine
therapeutics that sequester or block aCGRP or the CGRP receptor.
This problem is further exacerbated by the fact that women are pre-
dominantly affected by migraine and osteoporosis. Indeed, approxi-
mately 54 million of the U.S. population have osteoporosis and low
bone mass and on average 1 in 2 women and 1 in 4 men over the age
of 50 will suffer an osteoporotic fracture [8].
With regard to fracture and CGRP, as recently summarized [6],
several investigators have shown CGRP expression at the fracture site
and reported correlative findings. Prior to the studies reported in this
issue of EBioMedicine by Appelt et al. [1] perhaps the best evidencer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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injection with CGRP inhibitor significantly impaired fracture healing
in a rat model, as demonstrated by a significant reduction in mineral-
ized callus with an increase in cartilage [9]. In the current study,
Appelt et al. [1] first demonstrate that CGRP and its receptor, calcito-
nin receptor-like receptor (CRLR), are expressed during bone regen-
eration. They demonstrate profound impairment of bone
regeneration (0.7 mm femoral osteotomy) in aCGRP/ mice com-
pared to wild-type controls. Indeed, they show 66.66% of aCGRP/
mice display non-unions and 25% of aCGRP/ mice display delayed
unions. At the fracture site, they observed reductions in bone forming
osteoblasts and bone resorbing osteoclasts, both of which are
required for successful bone repair. Next, a series of mechanistic
studies demonstrated that the phenotype observed in aCGRP/
mice is not cell-autonomous, but rather is due to the lack of secreted
aCGRP to function in normal fracture repair. Fracture callus tissue
was then subjected to transcriptomic analyses and 170 genes differed
significantly in aCGRP/ mice compared to wild-type controls. As
may be expected in a fracture model, many of the identified genes
were known regulators of skeletal homeostasis and bone regenera-
tion. Finally, to determine whether the differentially regulated genes
observed in fracture repair were altered due to the interaction of
aCGRP with its receptor, CRLR, bone marrow cells were treated with
recombinant aCGRP or olcegepant (CRLR antagonist), and many of
the genes which were identified in genome wide analyses were sig-
nificantly increased with aCGRP treatment and decreased with olce-
gepant treatment. Overall, the findings of Appelt, et al. [1]
compellingly demonstrate the important role of secreted aCGRP in
fracture repair.
With the growing body of evidence demonstrating the important
role of aCGRP in successful fracture repair and the regulation of bone
mass, long-term consequences of CGRP antagonists, especially on bone
mass and fracture healing in women, must be considered. This then
begs the question whether use of CGRP/CGRP receptor targeted thera-
pies to reduce migraine pain will also increase our risk of developing
osteoporosis and/ or preclude fracture healing. Understanding these
possible consequences will require additional clinical investigations.Declaration of Competing Interest
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